<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04795882</url>
  </required_header>
  <id_info>
    <org_study_id>UCL 129642</org_study_id>
    <nct_id>NCT04795882</nct_id>
  </id_info>
  <brief_title>A New Study Evaluating the Activity of Modular CAR T for mYeloma</brief_title>
  <acronym>MCARTY</acronym>
  <official_title>An Open Label, Phase 1 Study Evaluating the Activity of Modular CAR T for mYeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 rolling 6 trial design evaluating safety of a novel BCMA Chimeric Antigen&#xD;
      Receptor (CAR) alone and of CAR T cells engineered to co-express BCMA CAR and a CD19 CAR in&#xD;
      patients with relapsed / refractory Multiple Myeloma.&#xD;
&#xD;
      The study will assess the feasibility of generating these Advanced Therapy Investigational&#xD;
      Products (ATIMPs) and the safety of administering the CAR T cells (either BCMA alone or&#xD;
      co-expressed with CD19) in patients with relapsed / refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 rolling 6 trial design evaluating safety of a novel BCMA CAR alone and of&#xD;
      CAR T cells engineered to co-express BCMA CAR and a CD19 CAR in patients with triple&#xD;
      refractory Multiple Myeloma.&#xD;
&#xD;
      The first 3-6 patients will be treated at the lower dose of BCMA CAR T cells in cohort 1 (50&#xD;
      x 10^6 cells). If the lower dose is deemed tolerable, recruitment into cohort 1 at a higher&#xD;
      dose (150 x 10^6 BCMA CAR T cells) and cohort 2 at a dose of 50 x 10^6 BCMA/CD19 cells will&#xD;
      begin in parallel.&#xD;
&#xD;
        -  If the 50 x 10^6 cells BCMA/CD19 CAR dose in cohort 2 is deemed intolerable, then no&#xD;
           further patients will be recruited to cohort 2.&#xD;
&#xD;
        -  If both 150 x 10^6 cells BCMA CAR (cohort 1) and 50 x 106 cells BCMA/CD19 CAR (cohort 2)&#xD;
           are deemed tolerable then recruitment will begin to a higher BCMA/CD19 CAR dose of 150 x&#xD;
           10^6 cells.&#xD;
&#xD;
        -  If 150 x 10^6 cells BCMA CAR is intolerable and 50 x 10^6 cells BCMA/CD19 CAR is&#xD;
           tolerable then no further patients will be recruited to cohorts 1 or 2.&#xD;
&#xD;
      A Summary of dosing on trial is outlined below:&#xD;
&#xD;
      Cohort 1 (BCMA CAR-T cells)&#xD;
&#xD;
        -  Dose level 1: 50x10^6 BCMA CAR-T cells&#xD;
&#xD;
        -  Dose level 2: 150x10^6 BCMA CAR-T cells&#xD;
&#xD;
      Cohort 2 (BCMA/CD19 CAR-T cells)&#xD;
&#xD;
        -  Dose level 1: 50x10^6 BCMA/CD19 CAR-T cells&#xD;
&#xD;
        -  Dose level 2: 150x10^6 BCMA/CD19 CAR-T cells&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2022</start_date>
  <completion_date type="Anticipated">September 1, 2035</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Rolling 6 trial design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity evaluated by the incidence of grade 3-5 toxicity causally related to the Advanced Therapy Investigational Product (ATIMP)</measure>
    <time_frame>28 days</time_frame>
    <description>The incidence of grade 3-5 toxicity assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 and the American Society for Transplantation and Cellular Therapy (ASTCT) Cytokine Release Syndrome (CRS) and Neurotoxicity tool</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of manufacturing CAR T-cells evaluated by the number of therapeutic products generated</measure>
    <time_frame>30 days</time_frame>
    <description>Feasibility of generation of CAR T cells as evaluated by the number of therapeutic products generated.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Cohort 1: BCMA CAR T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Advanced Therapy Investigational Product (ATIMP): BCMA CAR T-cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: BCMA/CD19 CAR T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Advanced Therapy Investigational Product (ATIMP): BCMA/CD19 CAR T-cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCMA CAR T cells</intervention_name>
    <description>Infusion with ATIMP: BCMA CAR T-cells</description>
    <arm_group_label>Cohort 1: BCMA CAR T cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCMA/CD19 CAR T cells</intervention_name>
    <description>Infusion with ATIMP: BCMA/CD19 CAR T-cells</description>
    <arm_group_label>Cohort 2: BCMA/CD19 CAR T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18&#xD;
&#xD;
          2. Relapsed/Refractory Multiple Myeloma&#xD;
&#xD;
          3. Secretory disease: PP≥5g/L and/or sFLC≥100mg/L of involved light chain with abnormal&#xD;
             K:L ratio.&#xD;
&#xD;
          4. ≥3 prior lines of therapies (including proteasome inhibitor, IMiD, anti CD38 antibody)&#xD;
&#xD;
          5. Refractory to last line of therapy (not achieved at least PR and progressed within 60&#xD;
             days of last dose or achieved at least PR but progressed within 6 months of last dose)&#xD;
&#xD;
          6. Has previously received or is not suitable for ASCT&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status 0/1&#xD;
&#xD;
          8. Creatinine Clearance (CrCl)≥60ml/min, Absolute Neutrophil Count (ANC)≥1x10^9/L,&#xD;
             Platelets (plt)≥50x10^9/L, Haemoglobin (Hb)≥80 /L, lymphocyte count ≥0.3x10^9/L&#xD;
&#xD;
          9. Patients must weigh &gt;30 kg&#xD;
&#xD;
         10. Agreement to have a pregnancy test, use adequate contraception (if applicable)&#xD;
&#xD;
         11. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous diagnosis of systemic light chain amyloidosis&#xD;
&#xD;
          2. Prior treatment with investigational or approved gene therapy or cell therapy products&#xD;
             or allogenic stem cell transplant will be excluded&#xD;
&#xD;
          3. Stem cell transplant patients only:&#xD;
&#xD;
               -  allogeneic stem cell transplant within 12 months prior to registration into the&#xD;
                  study&#xD;
&#xD;
               -  moderate/ severe chronic GVHD (NIH consensus criteria) requiring&#xD;
                  immunosuppressive therapy and/or systemic steroids&#xD;
&#xD;
          4. Oxygen saturation ≤ 90% on air&#xD;
&#xD;
          5. Patients with clinically significant, uncontrolled heart disease or a recent (within 6&#xD;
             months) cardiac event&#xD;
&#xD;
          6. Left ventricular ejection fraction &lt; 50% (ECHO or MUGA)&#xD;
&#xD;
          7. Corrected QT interval (QTc)&gt;470 ms on ECG&#xD;
&#xD;
          8. Uncontrolled cardiac arrhythmia (patients with rate-controlled atrial fibrillation are&#xD;
             not excluded)&#xD;
&#xD;
          9. History or evidence of deep vein thrombosis or pulmonary embolism requiring ongoing&#xD;
             therapeutic anticoagulation at preconditioning&#xD;
&#xD;
         10. Chronic renal impairment requiring dialysis, or creatinine clearance &lt;60ml/min&#xD;
&#xD;
         11. Patients with significant liver disease: alanine aminotransferase or aspartate&#xD;
             aminotransferase ≥3x upper limit normal (ULN), or total bilirubin ≥25umol/L&#xD;
             (1.5mg/dL), except in patients with Gilbert's syndrome, or evidence of end-stage liver&#xD;
             disease (e.g. ascites, hepatic encephalopathy)&#xD;
&#xD;
         12. Patients with any major surgical intervention in the last 3 months, cement&#xD;
             augmentation for vertebral collapse is permitted&#xD;
&#xD;
         13. Patients with active gastrointestinal bleeding&#xD;
&#xD;
         14. Patients with active infectious bacterial or viral disease requiring treatment&#xD;
&#xD;
         15. Known active central nervous system involvement of MM. History or presence of&#xD;
             clinically relevant central nervous system pathology such as epilepsy, paresis,&#xD;
             aphasia, stroke within 3 months prior to enrolment, severe brain injuries, dementia,&#xD;
             Parkinson's disease, cerebellar disease, organic brain syndrome, uncontrolled mental&#xD;
             illness, or psychosis&#xD;
&#xD;
         16. Patients receiving corticosteroids at a dose of &gt;5 mg prednisolone per day (or&#xD;
             equivalent) that cannot be discontinued&#xD;
&#xD;
         17. Use of rituximab (or rituximab biosimilar) within the last 3 months prior to CAR&#xD;
             T-cell infusion&#xD;
&#xD;
         18. Active autoimmune disease requiring immunosuppression&#xD;
&#xD;
         19. Past or current history of other neoplasms&#xD;
&#xD;
         20. Received any radiotherapy within the last 7 days prior to lymphodepletion or&#xD;
             leukapheresis. Localised radiation to a single site, e.g. for bone pain is permitted&#xD;
             at any time&#xD;
&#xD;
         21. Patients with any anti-myeloma therapy within the last 7 days prior to LD or&#xD;
             leukapheresis&#xD;
&#xD;
         22. Inability to tolerate leucapheresis&#xD;
&#xD;
         23. Life expectancy &lt;3 months&#xD;
&#xD;
         24. Women who are pregnant or breastfeeding&#xD;
&#xD;
         25. Known allergy to albumin or DMSO&#xD;
&#xD;
        For CAR T-cell infusion:&#xD;
&#xD;
          1. Active infection requiring systemic anti-microbial therapy, or with temperature more&#xD;
             or equal to 38 C within 48 hours before scheduled CAR-T cell infusion&#xD;
&#xD;
          2. Requirement for supplementary oxygen at the time of scheduled CAR-T cell infusion&#xD;
&#xD;
          3. Clinical deterioration of organ functions (hepatic or renal function) exceeding&#xD;
             criteria set at study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>MCARTY Trial Coordinator</last_name>
    <phone>02076799599</phone>
    <email>ctc.MCARTY@ucl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kwee Yong</last_name>
    <email>kwee.yong@ucl.ac.uk</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

